Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique.
OBJECTIVE
To report the effect of intrastromal injection of bevacizumab in an eye with extensive corneal stromal vascularization after deep anterior lamellar keratoplasty.


METHODS
Bevacizumab (2.5 mg/1 mL) was injected into the deep corneal stroma of an eye with severe and extensive stromal vascularization.


RESULTS
Corneal vascularization regressed dramatically after deep stromal injection of bevacizumab with no recurrence after 6 months. Visual acuity was improved, and the patient's complaints subsided.


CONCLUSIONS
Corneal intrastromal injection of bevacizumab can be considered for management of intrastromal vascularization after deep anterior lamellar keratoplasty.
Hashemian
Mohammad Naser
MN
Cornea Department, Eye Research Center, Farabi Eye Center, Tehran Medical University, Qazvin Square, Tehran, Iran. mahammadpour@yahoo.com
Zare
Mohammad Ali
MA
Rahimi
Firoozeh
F
Mohammadpour
Mehrdad
M
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000209:etiology* / Q000473:pathology; D003319:Corneal Stroma / Q000098:blood supply*; D016039:Corneal Transplantation / Q000009:adverse effects* / Q000379:methods*; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab